Pediatric Cardiology, Gregorio Marañon General University Hospital, Madrid, Spain.
Catheter Cardiovasc Interv. 2022 Jan 1;99(1):E38-E42. doi: 10.1002/ccd.29985. Epub 2021 Oct 21.
Pulmonary percutaneous valve implantation (PPVI) is feasible with satisfactory mid-term results in patients with native right ventricular outflow tract (RVOT) and has been increasingly used instead of surgically implantable pulmonary valves. Creating a stable landing zone with a diameter less than the largest commercially available valve (previously available 29 mm and currently available 32 mm) is crucial for technical success of the procedure, limiting the number of suitable candidates for PPVI. We report the case of PPVI with a 32 mm Myval transcatheter heart valve in a patient with a large native RVOT (pre-stented with AndraStent XXL mounted on a 35 × 60 mm valve balloon catheter) lesion who had Tetralogy of Fallot surgically corrected. The post-procedural outcomes of this case were satisfactory with no complications reported during the hospital stay.
经皮球囊肺动脉瓣植入术（PPVI）在伴有先天性右心室流出道（RVOT）病变的患者中是可行的，且中期结果令人满意，已逐渐替代外科可植入肺动脉瓣。对于该手术技术的成功，关键是要创建一个稳定的瓣环，其直径要小于最大的商业可用瓣膜（先前的 29mm 及目前的 32mm），这也限制了适合行 PPVI 的患者数量。我们报告了一例在经皮预扩张（使用 AndraStent XXL 支架置于 35×60mm 瓣膜球囊导管上）先天性 RVOT 较大（病变处）患者中应用 32mmMyval 经导管心脏瓣膜行 PPVI 的病例，该患者曾行法洛四联症矫治术。该病例的术后结果令人满意，在住院期间未报告任何并发症。
